No clinical trial has measured whether testosterone therapy lowers circulating pregnenolone in men. The guides we publish here start from what somebody measured, and on this question nobody has measured anything.
The idea that testosterone shuts down the entire steroid pathway is common across patient forums. Men read that an upstream deficiency explains fatigue, mood shifts, or brain fog, and that an over-the-counter supplement restores hormonal balance. That narrative sounds logical on the surface, but it conflates testicular suppression with total hormonal production.
The Verdict
What Anyone Has Actually Measured
No published study has measured serum pregnenolone concentrations in men before and after starting testosterone replacement therapy. A search across PubMed, PMC, and the entire interventional registry on ClinicalTrials.gov reveals zero clinical trials documenting how exogenous testosterone shifts circulating pregnenolone in humans. The popular claim that therapy depletes this steroid rests entirely on theoretical deduction rather than physical measurement.
Clinical studies examining hypothalamic-pituitary-gonadal axis suppression routinely track other hormones while ignoring upstream precursors. In a trial of 30 healthy men aged 19 to 32 pharmacologically castrated with degarelix and administered 1000 mg of testosterone undecanoate, researchers measured testosterone, estradiol, luteinizing hormone, and follicle-stimulating hormone. Pregnenolone was omitted from the laboratory panel. Similarly, an extensive published review of testosterone therapy and anabolic steroid-induced hypogonadism tracked testosterone, dihydrotestosterone, and estradiol, leaving the upstream steroid cascade completely unmeasured.
Observational data linking circulating levels shows a weak relationship at best. In an occupational study of 88 male workers, serum pregnenolone and total testosterone correlated only modestly, with a Pearson correlation coefficient of 0.26. That evaluation relied on an enzyme-linked immunosorbent assay rather than gold-standard mass spectrometry. Without longitudinal data measuring men before and during therapy, the exact effect of exogenous testosterone on circulating concentrations remains unknown.
| Study or Publication | Hormones Measured | Pregnenolone Measured | Key Takeaway |
|---|---|---|---|
| Degarelix and testosterone undecanoate trial (30 men) | Testosterone, estradiol, LH, FSH | No | Upstream steroid precursors were entirely omitted from the blood panel |
| Systematic review on HPG axis suppression | Testosterone, DHT, estradiol | No | Addressed downstream androgens without evaluating upstream pathway shutdown |
| Occupational study in male workers (88 men) | Pregnenolone, total testosterone | Yes (ELISA) | Found a weak correlation (r = 0.26) using immunoassay methods |
| ClinicalTrials.gov interventional database (48 trials) | Psychiatric and neurological rating scales | No | Zero trials listed serum testosterone as a primary or secondary outcome |
How Steroid Pathways Split Between Testes and Adrenals
Pregnenolone synthesis occurs in both the testes and the adrenal glands through distinct regulatory mechanisms that respond differently to exogenous testosterone. In all steroidogenic tissue, the conversion of cholesterol to pregnenolone represents the initial, rate-limiting step of steroid synthesis. The enzyme CYP11A1, also known as cytochrome P450 side-chain cleavage, removes six carbons from cholesterol through a three-step oxidation process.
In the testes, this process depends on pituitary signaling. Luteinizing hormone binds to Leydig cell receptors, triggering cyclic adenosine monophosphate to stimulate steroidogenic acute regulatory protein, which delivers cholesterol to mitochondrial enzymes. When a man begins testosterone replacement therapy, exogenous hormones trigger negative feedback at the hypothalamus and pituitary gland. This feedback diminishes luteinizing hormone release, suppressing testicular steroidogenesis and dropping intratesticular testosterone levels by more than 80%.
The adrenal pathway operates under completely separate physiological control. Adrenal steroidogenesis is driven by adrenocorticotropic hormone binding to melanocortin 2 receptors, which stimulates CYP11A1 independently of gonadotropins. Exogenous testosterone does not suppress adrenocorticotropic hormone. Because no published study has quantified the proportion of circulating pregnenolone derived from adrenal tissue versus testicular tissue, suppressing testicular output does not eliminate whole-body synthesis.
The Missing Link Between Oral Pregnenolone and Testosterone
No clinical trial has demonstrated that taking an oral pregnenolone supplement increases serum testosterone levels in humans. Among the 48 registered interventional studies on ClinicalTrials.gov, none evaluate total or free testosterone as an outcome in a treatment arm. Instead, human trials on oral pregnenolone focus exclusively on psychiatric and neurological disorders.
In a clinical trial evaluating 120 patients with schizophrenia, researchers administered doses titrated up to 500 mg daily over eight weeks. The treatment arm showed no significant improvement over placebo on the primary composite cognitive score, although secondary functional capacity scores improved. An earlier pilot study using 500 mg daily reported reductions in negative psychiatric symptoms, while a separate trial of 60 patients reported negative symptom reductions at just 50 mg daily. The larger trial used a tenfold higher dose and failed to reproduce those specific benefits.
A pharmacokinetic trial in 31 healthy men demonstrated that oral supplementation does not increase downstream androgens. Participants received a single 400 mg oral dose of pregnenolone, which produced a threefold rise in serum pregnenolone and a sevenfold rise in allopregnanolone after three hours. Dehydroepiandrosterone levels dropped non-significantly by approximately 5%, and cortisol concentrations were unaffected. Even large oral doses failed to push hormonal traffic into downstream androgen pathways.
Pharmacokinetics and Neurosteroid Mechanisms
Pregnenolone functions primarily as a neurosteroid precursor within the central nervous system. Rather than acting on classic nuclear androgen receptors, its metabolites modulate ligand-gated ion channels. Allopregnanolone acts as a potent positive allosteric modulator of gamma-aminobutyric acid type A receptors, binding between the beta-subunit and alpha-subunit transmembrane helices to increase channel conductance and promote neuronal inhibition.
Pregnenolone sulfate exhibits the opposite neurochemical profile by acting as a positive allosteric modulator at NMDA receptors. Despite widespread public interest in these neurological pathways, basic pharmacokinetic data in humans remains limited. In a pilot pharmacokinetic evaluation of seven participants, oral administration produced significant elevations in plasma levels compared to placebo, but the authors explicitly noted that fundamental parameters including absolute oral bioavailability, absorption rate, and elimination half-life remain uncharacterized in published literature.
Why Clinical Guidelines Do Not Include Pregnenolone Monitoring
Major medical specialty organizations do not recommend testing or supplementing pregnenolone for men on testosterone therapy. The clinical practice guideline published by the Endocrine Society focuses monitoring on objective parameters: evaluating symptoms, checking hematocrit and serum testosterone, and assessing prostate safety. The Endocrine Society guideline does not mention pregnenolone anywhere in its text.
The guideline from the American Urological Association outlines an identical conservative framework. Table 7 of the document specifies exactly six follow-up laboratory markers: total testosterone, luteinizing hormone, follicle-stimulating hormone, prolactin, estradiol, and hematocrit alongside prostate-specific antigen. Specialty societies exclude pregnenolone because no clinical evidence demonstrates that monitoring or manipulating its concentration improves patient outcomes.
| Laboratory Marker | AUA Guideline Inclusion | Endocrine Society Inclusion | Clinical Rationale for Monitoring |
|---|---|---|---|
| Total Testosterone | Yes (Table 7) | Yes | Confirms therapeutic target range and symptom resolution |
| Hematocrit | Yes (Table 7) | Yes | Monitors for polycythemia to keep levels below 54% |
| Estradiol | Yes (Table 7) | Optional / Symptom-driven | Assesses aromatization in symptomatic individuals |
| Prostate-Specific Antigen | Yes (Table 7) | Yes | Screens for prostate abnormalities during therapy |
| Pregnenolone | No | No | Zero outcome trials support clinical utility or safety targets |
Reference Ranges and Laboratory Assay Challenges
Interpreting a single pregnenolone blood test is notoriously difficult due to extreme baseline variability across healthy populations. In a reference-interval study of 525 fasting individuals evaluated by liquid chromatography-tandem mass spectrometry, the male plasma median was 5.13 nmol/L with a reference range spanning from 1.45 to 22.88 nmol/L. This represents an almost 16-fold difference between the lower and upper limits of normal health.
Age produces a dramatic physiological decline in circulating concentrations. In the same mass spectrometry study, the upper reference cut-off dropped from 30.8 nmol/L in 22-year-old men to 8.0 nmol/L in 70-year-old men, representing a 74% decrease across the lifespan. A reading that appears low when compared against young adult cohorts may reflect normal age-adjusted physiology.
Testing technology introduces substantial analytical error. Standard clinical immunoassays frequently suffer from antibody cross-reactivity with related steroid compounds. Published cross-reactivity evaluations demonstrate that pregnenolone sulfate produces greater than 0.5% interference on commercial DHEA-sulfate immunoassays, while 5-alpha-pregnenolone cross-reacts up to 4.9% on standard progesterone assays. Accurate assessment requires liquid chromatography-tandem mass spectrometry rather than standard automated hospital platforms.
Regulatory Classifications and Anti-Doping Rules
The legal status of pregnenolone reflects conflicting interpretations among regulatory bodies. Under the Dietary Supplement Health and Education Act, the Food and Drug Administration does not approve dietary supplements prior to commercial sale. Manufacturers must ensure claims are truthful and non-misleading, but pre-market efficacy trials are not required for over-the-counter distribution.
The FDA takes enforcement action when manufacturers make unapproved medical claims. In a Warning Letter issued to Delano Company Inc., the FDA established that marketing pregnenolone to treat depression, bipolar disorder, or schizophrenia classified the product as an unapproved new drug. The agency restricted marketing claims without removing the substance itself from the over-the-counter supplement category.
Athletic organizations maintain a substantially stricter view. The US Anti-Doping Agency states that pregnenolone is classified as an unapproved new drug that cannot legally be included in dietary supplements or compounded preparations. USADA simultaneously notes that pregnenolone is absent from the World Anti-Doping Agency Prohibited List and confirms that no clear scientific evidence demonstrates it enhances hormone levels or athletic performance.
Evidence Gaps and Clinical Evaluation Limits
Men who experience persistent fatigue, low libido, or brain fog while on testosterone therapy will not find clinical evidence supporting pregnenolone supplementation. Those symptoms frequently stem from suboptimal dosing intervals, sleep disruption, elevated hematocrit, or thyroid abnormalities. Addressing documented variables on a standard men's hormone panel provides measurable diagnostic clarity that unvalidated neurosteroid panels cannot offer.
The current literature leaves substantial questions unanswered. A controlled trial measuring serum pregnenolone via mass spectrometry in men before and after starting testosterone therapy would establish whether a genuine deficiency occurs. Until that research exists, adding an unregulated precursor remains an unproven strategy. When evaluating persistent symptoms, clinicians examine verified markers on a comprehensive estradiol and androgen panel rather than speculative upstream targets.
Frequently Asked Questions
Does TRT lower pregnenolone?
Nobody has measured whether testosterone replacement therapy lowers circulating pregnenolone in humans. The hypothesis originates from testicular physiology: exogenous testosterone suppresses luteinizing hormone, which turns down steroid production in the testes. However, the adrenal cortex also synthesizes pregnenolone under the control of adrenocorticotropic hormone, which remains uninhibited during testosterone therapy. Because researchers have never quantified the ratio of testicular to adrenal contribution in men, it is impossible to determine whether circulating levels fall significantly or remain stable on therapy.
Should pregnenolone be tested on TRT?
Major medical guidelines do not recommend testing pregnenolone for men on testosterone therapy. Neither the Endocrine Society nor the American Urological Association includes pregnenolone in their laboratory monitoring recommendations. Routine follow-up focuses on total testosterone, hematocrit, estradiol, and prostate-specific antigen. Furthermore, standard laboratory immunoassays exhibit high rates of cross-reactivity with other steroid molecules, and population reference ranges vary up to 16-fold. Testing often produces ambiguous numbers that lack clinical guidelines for action.
Does pregnenolone raise testosterone?
No clinical trial has demonstrated that taking oral pregnenolone increases serum testosterone levels in men. Across 48 registered interventional studies on ClinicalTrials.gov, none report serum or free testosterone as an outcome in a pregnenolone arm. In a trial where 31 healthy men took a large 400 mg oral dose, circulating allopregnanolone climbed sevenfold, but dehydroepiandrosterone dropped slightly and cortisol was unchanged. The compound metabolized into downstream neurosteroids without stimulating the androgenic pathway.
What does pregnenolone actually do in the body?
Pregnenolone is the primary biological precursor for all human steroid hormones. In the adrenal glands, gonads, and brain, the enzyme CYP11A1 converts cholesterol into pregnenolone, which then branches out into mineralocorticoids, glucocorticoids, and sex hormones. Beyond its role as a hormonal building block, pregnenolone acts as a neurosteroid. It metabolizes into allopregnanolone, which enhances inhibitory GABA-A receptor signaling, and pregnenolone sulfate, which modulates excitatory NMDA receptors in the central nervous system.
Is pregnenolone a hormone or a supplement?
Pregnenolone is both an endogenous steroid prohormone and a commercially available dietary supplement. Biologically, it is synthesized by human tissues to produce other hormones. Commercially, it is sold over the counter under the Dietary Supplement Health and Education Act, which does not require pre-market approval by the Food and Drug Administration. However, the US Anti-Doping Agency considers it an unapproved new drug, illustrating the complex regulatory status surrounding the substance.
What is a normal pregnenolone level for a man?
Defining a normal pregnenolone level is difficult because published reference ranges are exceptionally wide. In a mass spectrometry study of 525 healthy individuals, male reference ranges spanned from 1.45 to 22.88 nmol/L, an almost 16-fold difference. In addition, concentrations decline sharply with age: the upper reference limit drops by 74% between age 22 and age 70. Without age-stratified testing performed by liquid chromatography-tandem mass spectrometry, a single blood test value is nearly impossible to interpret accurately.
Why do TRT clinics test pregnenolone if the guidelines do not?
Some private hormone clinics test pregnenolone based on theoretical biochemistry rather than established clinical trial evidence. Practitioners who test it assume that shutting down luteinizing hormone starves upstream steroid pathways, leading to a neurosteroid deficiency that causes fatigue or cognitive changes. While this biological hypothesis is plausible, it overlooks adrenal production and lacks validation in published outcome studies. Neither the Endocrine Society nor the American Urological Association lists pregnenolone among its follow-up markers, so a clinic that tests it is working outside both published monitoring protocols.